These results point to NK cells as the original source of IFN-ɣ and indicate the importance of CCL5/IFNG-CXCL9/10 axis for the clinical efficacy of anti-HER2 antibody-based treatment in primary HER2 + breast cancer patients. Here, CCL5 is linked to breast carcinoma.